Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug
Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...
Vertex Pharmaceuticals gets CHMP opinion recommending Kaftrio label expansion
Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
precisionmedicineonline1d
CHMP Recommends Vertex's Kaftrio, Kalydeco Combo for Additional Cystic Fibrosis Patients
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
pharmaphorum1d
Celebrations as NHS England agrees deal for Vertex’ cystic fibrosis triple
Kaftrio is the first drug that works in patients with the F508del and MF mutations, who account for around 90% of the overall CF population, and in trials led to improved lung function as well as ...
Hosted on MSN18d
Vertex's Revenue Surges but EPS Slips
This top-line improvement was largely due to the continued success of its cystic fibrosis lineup, particularly Trikafta/Kaftrio. However, non-GAAP earnings per share (EPS) of $3.98 fell short of the ...
Vertex Raises Guidance Despite Q2's Bottom-Line Losses
In the realm of gene-editing therapies, Vertex has launched Casgevy, an ex-vivo gene-edited cell therapy for the severe blood disorders sickle cell disease and transfusion-dependent beta-thalassemia.
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio drive year-over-year sales.